• Skip to main content
  • Skip to footer
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Three-dimensional human cell culture model for studying Non-Alcoholic Fatty Liver Disease

August 11, 2016

Resource > Posters >

Three-dimensional human cell culture model for studying Non-Alcoholic Fatty Liver Disease


The European Association for Study of the Liver (EASL)

Filed under: Disease modeling and MASLD/MASH

3D human cell model for studyiny NAFLD EDIT |

Kostrzewski et al

Non-Alcoholic Fatty Liver Disease (NAFLD) is a growing concern worldwide and is set to become the most predominant cause of chronic liver disease. NAFLD describes a range of disease states from liver steatosis, which is the simplest and most common through to late-stage liver disease, cirrhosis, and liver cancer. There are currently no FDA-approved drugs for the treatment of NAFLD and there is a clear requirement for better models to understand disease progression and the molecular pathways underlying the disease. Currently available pre-clinical models, be it in vivo or in vitro, have a number of limitations and differ in regards to the degree of hepatocellular damage and metabolic alterations associated with disease development. Current in vitro models generally utilizes hepatocellular carcinoma-derived cell lines, which lack many of the biochemical properties of primary hepatocytes and fail to represent the complexity of the liver microenvironment and disease pathology.​

Here, we developed a fully human in vitro NAFLD model by culturing human hepatocytes in 3D. This model mimics the liver microarchitecture and supports hepatic functions over extended periods of culture, allowing the continual accumulation of fat deposits in the hepatocytes.

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025
  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
Cyber Essentials Logo